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Background: Glioblastoma (GBM) is the most common primary brain tumor and the most aggressive glial tumor. This
tumor is highly heterogeneous, angiogenic, and insensitive to radio- and chemotherapy. Here we have investigated the
progression of GBM produced by the injection of human GBM cells into the brain parenchyma of immunocompetent
mice.
Methods: Xenotransplanted animals were submitted to magnetic resonance imaging (MRI) and histopathological analyses.
Results: Our data show that two weeks after injection, the produced tumor presents histopathological characteristics
recommended by World Health Organization for the diagnosis of GBM in humans. The tumor was able to produce reactive
gliosis in the adjacent parenchyma, angiogenesis, an intense recruitment of macrophage and microglial cells, and presence
of necrosis regions. Besides, MRI showed that tumor mass had enhanced contrast, suggesting a blood–brain barrier
disruption.
Conclusions: This study demonstrated that the xenografted tumor in mouse brain parenchyma develops in a very similar
manner to those found in patients affected by GBM and can be used to better understand the biology of GBM as well as
testing potential therapies.
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Glioblastoma (GBM) represents the most common pri-
mary brain tumor and the most aggressive glial tumor,
leading to poor prognosis for patients in whom the aver-
age survival is 12 to 14 months after diagnosis, according
to the World Health Organization (WHO). Tumor mass
is highly heterogeneous, being composed of several cell
types that include not only neoplastic cells, but also nor-
mal astrocytes and microglia, as well as cells recruited* Correspondence: flima@icb.ufrj.br
1Instituto de Ciências Biomédicas, CCS – Bloco F, Universidade Federal do
Rio de Janeiro, 21949-590 Rio de Janeiro, Brazil
Full list of author information is available at the end of the article
© 2014 Garcia et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.from the bloodstream such as endothelial cells, mono-
cytes, and lymphocytes [1-3].
Because most GBM symptoms are non-specific, GBM
diagnosis may be suggested by MRI exams, but can only be
confirmed by histopathological analysis [4-6], which in
most cases is done when patients are already in advanced
stages of the disease. Contrast enhancement and necrotic/
hemorrhagic spots are the main outputs obtained with
MRI. In addition, GBM is one of the most angiogenic tu-
mors [7,8]. The presence of glomeruloid vessels is an im-
portant feature for diagnosis through histopathological
analysis, as well as cellular atypia, necrosis, and mitotic
figures [9,10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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microenvironment. Microglia, brain macrophages, and infil-
trating macrophages associated with this tumor compose
approximately 30% of tumor mass, and display an amoeboid
morphology typical of activated macrophagic cells [11,12].
Astrocytes and endothelial cells also interact with the tumor,
triggering key processes such as reactive gliosis and angio-
genesis, respectively. Currently, there is a growing body of
evidence suggesting that the brain microenvironment as a
whole favors GBM growth and spread [2,13].
At the onset of GBM, microenvironment plays an anti-
tumor role; however, once the tumor is established, tumor
cells escape immune surveillance and non-cancerous cells
begin to play a pro-tumorigenic role [14,15]. Most current
studies on GBM development have been done in nude mice
[16], in which the immune response is severely compro-
mised, thus failing to recapitulate some GBM–microenvir-
onment interactions [17]. Thus, an alternative model for
studying GBM that takes into account the immune re-
sponse is much needed for a better understanding of how
these interactions take place.
In this study, we developed an orthotopic xenotrans-
plant model of human GBM cells by inoculating im-
munocompetent mice. Our model presents important
features found in GBM patients and may further be used
to help develop novel therapeutic strategies to improve
the outcome of GBM patients.
Methods
Reagents
All culture media components as well as the secondary
antibodies conjugated with either Alexa Fluor 488 or Fluor
546 were obtained from Invitrogen–Life Technologies
(Carlsbad, CA, USA). All culture plates and flasks were
obtained from TPP (Zolstrasse, Trasadingen, Switzerland).
Glucose was purchased from Merck (Frankfurter,
Darmstadt, Germany), and Fungizone was purchased from
Bristol-Meyers Squibb (Princeton, NJ, USA). Rabbit anti-
glial fibrillary acidic protein (GFAP) and mouse anti-
Vimentin clone V9 antibodies were purchased from
DAKO (Produktionsvej, Glostrup, Denmark). Mouse anti-
CD31 antibody was purchased from Millipore (Billerica,
MA, USA). Biotinylated Griffonia simplicifolia Isolectin
B4 (IB4) was obtained from Vector (Burlingame, CA,
USA), and streptavidin-Cy3 and 4-6-diamino-2-phenylin-
dole (DAPI) were obtained from Sigma (Natik, MA,
USA). Mouse anti-IDH1–R132H antibody (clone H09)
was purchased from Dianova (Hamburg, Germany).
Animals
The use of laboratory animals in this study was approved
by the Ethics Committee of the Center for Health Sciences
(Centro de Ciências da Saúde – CCS) at the Federal Uni-
versity of Rio de Janeiro (Universidade Federal do Rio deJaneiro – UFRJ) (Protocol No. DAHEICB 015). The “Guide
for the Care and Use of Laboratory Animals” (published by
the National Academy of Science, National Academy Press,
Washington, D.C.) was strictly followed in all experiments.
All efforts were made to minimize the number of animals
used and their suffering. Male Swiss mice (SWR/J) of 10–
14 weeks of age, inbred strain were obtained from the Bio-
medical Sciences Institute at the Federal University of Rio
de Janeiro (UFRJ).
Maintenance of the GBM cell line
The human tumor cell line GBM95 was established in our
laboratory [18]. The use of patients’ surgical specimens for
the establishment of cell lines for in vitro and in vivo
research had the written informed consent from the patients
and was approved by the Brazilian Ministry of Health Ethics
Committee, under Institutional Review Board (IRB -
Research Ethics Committee of Hospital Universitário
Clementino Fraga Filho) consent CEP-HUCFF No. 002/01.
Cells were grown and maintained in DMEM-F12 sup-
plemented with 10% FBS. Culture flasks were maintained
at 37°C in a humidified 5% CO2 and 95% air atmosphere.
Cells displaying exponential growth were detached from
the culture flasks with 0.25% trypsin/ethylene-diamine tet-
raacetic acid (EDTA) and seeded. Cultured GBM95 cells
were immunoreactive for GFAP, vimetin and nestin [18],
but not labeled by IB4 (microglial marker; not shown).
Maintenance of the human astrocyte cells
Adult primary human astrocytes were isolated from surgi-
cally resected anterior temporal lobe tissue, from patients
selected for surgical treatment of temporal-lobe epilepsy
associated with hippocampus sclerosis. The pathological
tissue targeted in surgery for these cases is the gliotic
hippocampus, and the anterior temporal lobe resection is
used merely as a surgical pathway to the diseased area. All
patients gave written consent to the use of their surgical
specimens for isolation of cortical cells (including astro-
cytes) in the study, and the procedures were approved by
the Brazilian Ministry of Health Ethics Committee under
IRB consent (CEP-HUCFF No. 060/05). As previously de-
scribed [19], only healthy cortical tissue was used to pro-
duce astrocyte cultures. Briefly, tissues were washed in
DMEM medium, mechanically dissociated, chopped into
small pieces with a sterile scalpel, and incubated in 10 mL
of 0.25% trypsin solution at 37°C for 10 min. After centri-
fugation for 10 min, the cell pellet was resuspended in
DMEM/F12 growth medium supplemented with 10% fetal
calf serum (FCS), and plated onto tissue culture plates in a
humidified 5% CO2, 95% air atmosphere at 37°C for
2 hours in order to achieve adherence of microglial cells.
The nonadherent astrocytes were transferred into other
culture plates, previously coated with poly-L-lysine. Ad-
herent astrocytes were allowed to grow by replacing the
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ated by harvesting confluent astrocyte cultures using
trypsin-EDTA solution (0.25% trypsin with EDTA; Invitro-
gen, Carlsbad, CA, USA). Human astrocytes from up to
the third passage were used in this study and expressed
the human leukocyte antigen (HLA) and typical astrocyte
markers, such as GFAP and glutamate-aspartate trans-
porter (GLAST) attesting to their human and astrocytic
nature [19].
In vivo mouse glioma model
Male Swiss mice of 10–14 weeks of age weighing 30–35
grams were used. Mice were anesthetized with diazepam
(5 mg/kg i.m.), ketamine (100 mg/kg i.m.), and xylasine
(25 mg/kg i.m.), and then a brain midline incision was
made on the scalp. A small hole was drilled in the skull at
stereotaxic coordinates: 1 mm posterior to the bregma
and +2 mm mediolateral from the midline. 5 × 105
GBM95 cells (or human astrocytes – control) were deliv-
ered in 3 μL DMEM-F12 at a depth of 3 mm with a
Hamilton (Hamilton, Reno, Nevada, USA) syringe over
30 minutes. Animals were followed and analyses were
done after 14 days after tumor cell injection. Four animals
per group (GBM or astrocytes) were used for each experi-
ment described below.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) was performed 2, 7,
and 14 days after tumor cell injection. Mice were anesthe-
tized with ketamine (100 mg/kg i.m.) and xylazine
(25 mg/kg i.m.) and images were acquired with a 7-T
magnetic resonance scanner (7 T/210 horizontal Varian
scanner, Agilent Technologies). Brain images were ob-
tained using a Fast-Spin-Echo (FSE) T2 weighted (TE/TR:
15/2000 ms; matrix: 128×128; slice thickness: 1 mm; with
no gap; 12 averages), a FSE proton density (PD) (TE/TR:
10/2000 ms; matrix: 128x128; slice thickness: 1 mm; no
gap; 12 averages) and Spin-Echo (SE) T1 weighted (TE/
TR: 15/250 ms; matrix: 128x128; slice thickness: 1 mm;
with no gap; 12 averages) sequences in the axial (field of
view: 21.3 mm × 22.3 mm, in plane resolution: 0,166 mm
/ 0,174 mm), coronal (field of view: 25.4 mm × 25.4 mm,
in plane resolution: 0,198 mm / 0,198 mm), and sagittal
(field of view: 25.6 mm × 25.6 mm, in plane resolution:
0,20 mm / 0,20 mm) planes, before and after gadolinium
injection (0.05 M/Kg i.p.).
Prior to image analysis, datasets were inspected for arti-
facts and the brain morphology and tumor characteristics
were evaluated. Data processing was performed using
MRIcro-Software (http://www.mccauslandcenter.sc.edu) in
order to quantify MRI-hyperintensity volume tumor in each
animal scanned 7 days and 15 days after human GBM injec-
tion. Regions of interest were manually defined on consecu-
tive slices by two investigators on T2-weighted imagesbefore gadolinium administration and PD and T1 images
after gadolinium injection, obtained from three independent
experiments. Graphics were assembled using GraphPad
Prism 5.Tissue processing
Fourteen days after tumor cell injection, mice were
anesthetized and transcardially perfused with 4% para-
formaldehyde (PFA) in phosphate-buffered saline (PBS)
for perfusion-fixation. Brains were dissected, post-fixed
in cold 4% PFA for 24 hours, and stored at 4°C before
processing. Tissues were dehydrated in graded ethanol
series (30%, 40%, 50%, and 60% for 30 minutes, and then
70%, 80%, and 90% for 1 hour, and finally 100% twice
for 1 hour each time), followed by xylene overnight at
room temperature. Brains were then embedded in paraf-
fin for 3 hours at 67°C. Coronal sections were cut (5 μm
thick) on a microtome. Slices were stained with
hematoxylin and eosin and photographed using Nikon
Eclipse T300 and LABOMED Luxeo 4D microscopes.
The original hematoxylin-eosin stained histopatho-
logical slices of the patient’s biopsy upon which the
diagnosis of glioblastoma was made were also retrieved
from pathology files (Hospital Universitário Clementino
Fraga Filho (HUCFF)/UFRJ) and reviewed, as well as
photographed using the same microscope.Immunohistochemistry
For immunohistochemistry analysis, brains were quickly
excised after perfusion-fixation as described above and
serially sectioned at 50 μm. The sections were washed
with PBS and incubated with 10% NGS diluted in PBS
with 0.3% triton X-100 for 90 minutes. They were then
incubated with GFAP (1:400), CD31(1:100), Vimentin
(1:400) antibodies and with biotinylated IB4 (1:100)
overnight at 4°C, then washed again with PBS and incu-
bated with secondary antibodies conjugated with Alexa
Fluor 488 or 546 (1:400) and streptavidin-Cy3 (1:400)
for 2 hours. The sections were counterstained with
DAPI and coverslipped with fluoromount. Negative
controls were performed with non-immune rabbit IgG.
Slices were imaged using a confocal microscope (Leica
TCS-SP5) equipped with a 63x NA 1.40 oil-immersion
objective. Image processing was done using Adobe
Photoshop. Immunohistochemical staining was also
performed with IDH1 antibody (1:10,000) in 4 μm thick
tissue sections from paraffin blocks. The Universal LSAB™2
Kit/HRP, rabbit/Mouse-K0675 (Dako, Carpenteria, CA,
USA) detection system was used. Negative control con-
sisted of the reaction performed without primary antibody
and positive control consisted of a case of grade II
oligodendroglioma.
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Human glioblastoma xenograft growth in
immunocompetent mice brain
In order to evaluate human GBM progression in immuno-
competent mouse brains, we performed MRI and histo-
pathological analysis. MRI performed 2 days after GBM cell
implantation did not reveal blood–brain barrier (BBB) dis-
ruption (data not shown). However, MRI performed 7 and
14 days after tumor cell injection confirmed tumor growth
and mass formation with BBB disruption (Figure 1J–L;
Additional file 1). Figure 1 shows an axial view of a tumor-
bearing brain and Additional file 1 shows the increase of
the tumor mass volume at 7 and 14 days after cell injection.
In addition, two weeks after GBM cell injection, the MRI
also revealed hemorrhage and necrosis in the core of theFigure 1 Magnetic resonance imaging (MRI) 14 days after GBM95 cell t
superior-inferior sequence of the mouse brain shows a shift in brain midline a
contrast administration, enhanced contrast reflecting blood–brain barrier disru
(E–H). Scheme depicts the injection site of GBM95 cells in mouse brain. Datatumor mass, which was confirmed by later histological ana-
lyses. These MRI aspects are similar to those commonly
found in patients with GBM [5]. Furthermore, histological
analyses showed that the xenografted tumor infiltrates the
brain parenchyma, forming a solid tumor mass (Figure 2A),
and presents all microscopic histopathological features
required for the diagnosis of GBM according to the WHO
classification [1,4,20], namely cellular atypia, presence
of mitotic figures, endothelial vascular proliferation includ-
ing formation of glomeruloid vessels, and/or necrosis
(Figures 2A–C). The same characteristics were detected
in the patient’s original biopsy material (Figure 2E). In
contrast, injections of healthy human astrocytes did not
induce tumor mass development at 14 (Figure 2D) or
30 days (see Additional file 2) after injection of theseransplantation into one representative mouse brain. (A–D) T2
nd collapse of lateral ventricles. (I–L) T1 superior-inferior sequence after
ption in comparison to T1 sequence before contrast administration
are representative of four separate experiments.
Figure 2 Histopathological and immunohistochemical characteristics of the tumor mass within mouse brain parenchyma 14 days after cell
implantation, and of the original patient’s biopsy. A, Neoplastic cells forming a circumscribed solid tumor mass into brain tissue (black asterisk);
the blue asterisk indicates a necrosis area in the core of the tumor mass. B, Neoplastic cells showing prominent anaplasia and mitotic figures (arrow >
inset). C, Glomeruloid vessels (*). D, Human astrocytes inoculated in mouse brain; no tumoral mass is formed. Data are representative of four separate
experiments. E, Microscopic analysis of the patient’s original biopsy showing anaplastic cells (*, top right) and tumoral necrosis (bottom left). F and G,
Negative immunostaining for IDH1–R132H mutation in both tumor mass within mouse brain parenchyma (F) and in patient’s biopsy material (G). H,
Grade II oligodendroglioma, a positive control case of the IDH1–R132H mutation. Scale bars, 100 μm (A); 50 μm (B, E, H); 80 μm (C, D); 30 μm (F, G).
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human tumor cell line, the GBM02 [18] injected in a dis-
tinct mouse strain (C57/Black6), and the results were similar
to those found in this work (data not shown).
Xenografted GBM cells show the same negative result for
IDH1–R132H mutation as the original tumor
Since glioblastoma cases negative for IDH1 mutation tend
to be those primary and more aggressive glioblastomas
[21], we evaluated the presence of IDH1–R132H mutationby immunohistochemistry in order to verify if the tumor
cells injected in mouse brain tissue were able to maintain
this same characteristic from the original tumor. Both ma-
terials proved to be negative for IDH1–R132H mutation
(Figure 2F–H).
Xenografted GBM cells express human vimentin and
promote reactive gliosis in mouse brain tissue
We confirmed the human origin of the tumor in the
mouse brain two weeks after inoculation using a specific
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expected, no vimentin+ cells were observed in the contralat-
eral hemisphere (not shown). GBM induces reactive gliosis
in surrounding brain tissues, which is characterized by mor-
phological changes, increase in GFAP immunoreactivity and
cellular distribution, besides the release of pro-inflammatory
cytokines [22,23]. In Figure 3E–F, GFAP+ reactive cells
present an unusual palisade-like distribution irradiating from
the borders of tumor mass, whereas GFAP-stained astro-
cytes present regular morphology in the contralateral hemi-
sphere (Figure 3C, D).Figure 3 The tumor expresses human vimentin (hVim) and induces re
injected in the striatum of immunecompetent mice 14 days before the imm
tumor mass (A), depicted by cell nuclei atypia (DAPI counterstaining in cya
line, inset, and arrowheads) attest human origin of the tumor. (C–D) GFAP
stellate morphology. (E–F) In contrast, in the injected hemisphere, GFAP+ c
from the core of the tumor mass (delimited by the dashed line and indicat
bar, 40 μm. cc = corpus callosum; lv = lateral ventricle; Str = striatum.Xenografted tumor is highly angiogenic
Glioblastoma is one of the most angiogenic tumors,
although a marked imbalance between pro- and anti-
angiogenic factors in the tumor microenvironment results
in aberrant vessels [24]. We observed a high expression of
CD31 associated with abnormal blood vessels with fenes-
trated walls and variable diameter. The variable diameter
can also be noticed in the dissected tissue, indicating pro-
fuse angiogenesis (Figure 4). Near the necrotic area, we
can visualize enucleated endothelial cells along large cali-
ber blood vessels (Figure 4C, D). CD31 expression revealsactive gliosis in the adjacent brain parenchyma. GBM95 cells were
unohistochemical analysis. hVim staining (orange) at the core of the
n, inset) and at the border of the tumor mass (B, delimited by dashed
immunoreactivity cells in the contralateral hemisphere exhibit a
ells display a palisade arrangement of cell processes, which irradiate
ed by the asterisk). Data represent four separate experiments. Scale
Figure 4 Human GBM is highly angiogenic. (A–B) CD31 immunostaining (red) shows blood vessels displaying a regular morphology in the
contralateral hemisphere. (C–D) Disrupted wall of an irregular blood vessel (CD31+) in the injected hemisphere demonstrates a chaotic angiogenesis.
Cell nuclei counterstaining by DAPI (cyan). (C’) Macroscopic view of freshly dissected brain reveals the presence of irregular blood vessels (arrowheads)
and necrotic area (asterisk). Data represent four separate experiments. Scale bar, 40 μm.cc = corpus callosum; lv = lateral ventricle; Str = striatum.
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(Figure 4A, B).
Microglia are recruited to human GBM site
In contact with tumor cells, microglia infiltrate tumor mass
and acquire an amoeboid phenotype typical of activated
macrophages [25], as seen in Figure 5D, revealed by IB4
staining. Notice that positive-vimentin (tumor) cells are not
labeled for IB4 (Figure 5C), indicating that recruited micro-
glia are exclusively originated from brain parenchyma. As
shown in Figure 5A, contralateral hemisphere presents
ramified cells, characteristic of resident microglia.
Discussion
In this study, we used an ortothopic xenotransplant
model in immunocompetent mice that was able to re-
capitulate the human GBM features as described by the
WHO [4,26].
Current studies show that using orthotopic allotransplants
of murine glioma cell lines in immunocompetent animalsresults in a prominent tumor mass [27,28]. Nevertheless,
the histopathological features present in these tumors do
not reproduce the ones described in GBM patients, suggest-
ing that the allotransplanted tumor in mice cannot be com-
pared to an authentic human GBM [29].
In our model, despite the incompatibility of major
histocompatibility complex (MHC), we observed the
development of a tumor mass in immunocompetent
mice inoculated with human GBM cells. MRI analysis
of xenografted mice showed a growing tumor mass
(Additional file 1) which enhanced with MR contrast,
evidencing, BBB disruption (Figure 1), and the presence
of necrotic/hemorrhagic spots in the core of the tumor
mass, similar to what is described in GBM patients [10].
Moreover, we also observed the same histopathological
features present in GBM patients [9] as described by the
WHO (Figure 2). These similarities are compatible with
the development of human GBM tumor, as also indi-
cated by the presence of human vimentin-positive cells
in the entire tumor mass (Figure 3A).
Figure 5 Microglial cells are recruited from the mouse brain parenchyma. A, in the contralateral hemisphere we noted ramified microglia (IB4,
magenta; DAPI in cyan), whereas in the core of the tumor mass (B, DAPI in cyan) we observed hVim+ tumor cells (C, orange). D, In contact with GBM (hVim
+ cells, orange), infiltrated microglia exhibit amoeboid morphology (IB4, magenta). GBM95 cells were injected in the striatum of immunecompetent mice
14 days before the immunohistochemical analysis. Data represent four separate experiments. Scale bars, 40 μm. hVim=human vimentin. Cc = corpus
callosum; LV = lateral ventricle; Str = striatum.
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eral imaging and histological features with the GBM
commonly found in patients, we noticed that the bor-
ders of tumor mass in the mouse brain were rather cir-
cumscribed and not infiltrative (Figure 2A) like those
generally found in GBM patients. This difference, ob-
served by us and other groups that used in vivo glioma
models [30-32], may be due to a mismatch in cell sur-
face recognition proteins, mainly MHC, between mice
and humans [33]. Nevertheless, these probable differ-
ences in the tumor border in the mice did not affect
tumor development, which matched the diagnosis cri-
teria for GBM. Moreover, the fact that the tumor has
well-defined border (Figure 2A) does not invalidate the
diagnosis of a malignant neoplasia. Indeed, it resembles
the so-called malignant glioneuronal tumor (MGNT) de-
scribed by the team of Dr. Daumas-Duport as a more
superficial and fairly well-defined tumor, although highly
aggressive, causing recurrence and patient death [34].
The MGNT is classified by the WHO as a GBM.
The humanized mouse model, in which immunodefi-
cient mice are engrafted with human hematopoietic cells
or tissues, or mice that transgenically express human
genes [35,36], could be an alternative to deal with the
problem of the mismatch between mouse and human
MHC. Despite the advantages of this model, humanized
mice are onerous and they still present biological
constraints that could impair the proper function of its
immune response, i. e., innate immunity defects such as
decrease in macrophage function [37] and the lack of
human-specific adhesion molecules to improve appropri-
ate traffic of human cells [38].
We also verified that both the patient’s biopsy material
as well as the xenografted GBM cells injected into mousebrain were negative for IDH1–R132H mutation. This re-
cently described mutation in isocitrate desidrogenase
enzyme type 1 (IDH1) seems to be frequent in diffuse gli-
omas of astrocytic and oligodendroglial lineage, as well in
those secondary glioblastomas that derive from such tu-
mors [39]. In contrast, those primary and more aggressive
glioblastomas are generally negative for IDH1 mutation,
[21] and it seems that IDH-mutation is related to progno-
sis. Our results are in accordance with those already de-
scribed, since this was a case of primary glioblastoma, and
also show that xenografts are able to keep the IDH1 muta-
tion status of highly aggressive tumors. Although there are
other types of IDH1 mutation, the antibody used detects
the most common IDH1 mutation, which occurs in ap-
proximately 90% of cases, the R132H [40]. Thus, not only
are xenotransplant cells able to reproduce histopatho-
logical characteristics of malignancy found in glioblast-
omas, they can also reproduce the molecular status of one
the most important and recently described molecular
markers of prognosis in glioblastomas.
Reactive gliosis is triggered by brain injuries and
mainly consists of morphological changes and increase
in GFAP immunoreactivity [22,23]. As expected, we
observed GFAP+ cells displaying a palisade-like arrange-
ment in contrast to stellate astrocytes, which were dis-
tributed in the contralateral hemisphere and not in the
tumor area (Figure 3A). We also observed that our
ortothopic xenotransplant model produced a highly an-
giogenic tumor mass, which is known to be essential to
deliver nutrients and oxygen to the tumor [24,41]. Add-
itionally, we observed defective CD31+ vessels that pre-
sented fenestrated walls and variable calibers (Figure 4),
indicating that angiogenesis in the tumor mass is aber-
rant, as described in GBM patients [8,42]. Altogether,
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model for the study of human GBM progression in vivo.
GBM triggers BBB disruption leading to the invasion of
circulating monocytes that ultimately differentiate into mac-
rophages. These macrophages and locally recruited micro-
glia integrate into the tumor mass and are known as
glioma-associated microglia/macrophages (GAM) [43,44].
GAM play pivotal roles in GBM development, affecting gli-
oma growth, spread, angiogenesis, and local immunosup-
pression [25,30]. In our study we observed a massive
infiltration of IB4+ cells displaying amoeboid phenotype,
characteristic of activated macrophagic cells (microglia and
macrophages) (Figure 5). Although IB4 is not a specific
macrophage marker because it recognizes glycan moieties
that are also present in the endothelial cell surface, we did
not observe blood vessels labeled by IB4 in the tumor mass,
possibly due to the fact that vessels within the tumor are not
exclusively derived from endothelial cells, but also from
tumor cells [7,8].
Xenotransplant GBM models are currently performed
mostly in nude mice in which inoculated cells are able to
originate a tumor mass that nevertheless fails to reproduce
all the tumor stroma. Additionally, the tumor may not
present the main histopathological hallmarks of GBM
[45,46]. Although nude animals are widely used, they rep-
resent a limited model to investigate the interactions
established between immune cells, particularly recruited
monocytes, during tumor progression [17,47]. In contrast,
our orthotopic xenotransplanted model allows fully com-
prehensive studies on the interactions established between
tumor cells and GAM. For instance, it may allow unveiling
potential events triggered by immune responses and
aimed at preventing tumor formation. Additionally, our
model may also be used to investigate the hypothesis that
cellular interactions and the release of soluble inflamma-
tory mediators in the tumor microenvironment are
coopted by tumor cells, resulting in GBM progression.
These studies would not be possible with nude animals
[17,29].
Furthermore, nude animals are highly vulnerable to the
side effects of therapeutic cancer treatments thus hamper-
ing their application in pharmacological studies [48-50].
Tests with anti-tumor drugs using our model could have a
better outcome than that obtained with nude animals. In
fact, we have recently demonstrated that Equinatoxin II, a
pore-forming toxin from sea anemones, potentiates the ef-
fects of Etoposide in the induction of GBM cell death
[51]. In this study, we used human GBM cells xenografted
in the striatum of immunocompetent mice.
Conclusions
Here we report, for the first time, the occurrence of sev-
eral hallmark features of typical human GBM in a xeno-
transplant inoculated mouse model. Our model allowsthe study of molecular and cellular interactions during
GBM tumor progression that take place with active im-
mune response and may further be used to help develop
novel therapeutic strategies to improve the outcome of
GBM patients.
Additional files
Additional file 1: Figure S1. Magnetic resonance image analysis of
tumor volume at 7 and 14 days after human glioblastoma xenograft in
Swiss mice, showing the dynamics of glioblastoma’s growth. Tumor
volumes were measured on T2-weighted (T2) (before gadolinium (Gd)
injection) and on proton density (PD) images (after Gd injection). Values
are represented by median and standard error. Two-way analysis of
variance was used to compare tumor volumes at 7 and 14 days
(*p < 0.001). Data are representative of three separate experiments.
Additional file 2: Figure S2. Injections of human astrocytes did not
induce tumor mass development at 30 days after injection of these cells.
Hematoxilin–eosin staining of brain tissue. Data represent four separate
experiments. Scale bars, 100 μm (A, B); 50 μm (C, D).
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